Medium Healthcare – A healthcare consultancy firm in India

Consulting for business strategy, performance enhancement, marketing impact and service quality for the healthcare industry in India and other emerging economies

With a vision to spur innovation in the healthcare industy, Medium Healthcare Consultancy has been launched in India. Medium Healthcare aims to provide consulting services in the areas of business strategy, performance enhancement, marketing impact and service quality to healthcare organizations in India and other emerging economies.

Medium Heathcare Consulting helps its clients identify niche, but with significant potential, opportunities in healthcare in line with their overall objectives. These opportunities – typically aimed at a single or mix of specialties and focused target audience from a particular income segment – offer scope to emerge as viable, sustainable and scalable business models. Medium Healthcare also offers services in marketing of healthcare services with focus on enhancing revenue and profitability and service quality with a motto to maximize word-of-mouth referrals.

There are a few general consulting firms, which also have healthcare vertical. Healthcare consulting firms in India focus primarily on the project-related areas. Medium Healthcare intends to focus on business strategy and the softer’ side – marketing and service quality and is perhaps the only firm with this focus. The company plans to engage with existing healthcare players with a greater focus on emerging markets including India. It is also keen to advise newer entrants about the right healthcare strategy

Announcing the launch, Mr. Ratan Jalan, Founder & Principal Consultant, Medium Healthcare Consulting, said, “Almost everyone wants to build large, multi-specialty world-class hospitals in metros. It is a very myopic view, since the industry offers significant scope for innovation in alternative business models that are even more profitable and scalable.” He added, “In comparison to other service industries such as hospitality, banking or aviation, critical areas such as marketing and service quality continue to be handled in a fairly primitive manner in most healthcare organizations”.

“Within a few weeks, we have had very encouraging response from diverse players ranging from large, multi-specialty hospitals and small rural community hospitals on one hand to diagnostic services providers and healthcare architectural firms on the other”, he added.

You can visit www.med-ium.com

Fortis Healthcare strengthens presence in South by entering Karnataka

In tune with its strategy to expand its network rapidly and to strengthen its presence in Southern India, Fortis Healthcare Limited (“Fortis”), one of India’s leading private chain of hospitals, today announced its foray into the State of Karnataka. The Company through one of its wholly owned subsidiaries has now become a majority stake holder
in the Bangalore based Apollo RM Hospital, now rechristened Fortis Hospital, Seshadripuram.

The announcement is in line with Fortis’s plan to replicate its model to establish a network of super-specialty “centres of excellence” and multi-specialty hospitals to deliver quality healthcare to patients across the country. This will allow Fortis to leverage its knowledge of the healthcare sector and brand recognition to attract both doctors and patients to such facilities. This will be Fortis’s second project in South India after its investment in Malar Hospitals Limited in Chennai.

Fortis Hospital, Seshadripuram:

• Has 100 beds, which is expandable to 200 beds.
  
• It is a multi-specialty hospital situated in the well located Seshadripuram area of central Bangalore and
  
• Has a Centre of Excellence in Advanced Urology with specialized facilities for Urology, Nephrology and related specialties.
  

The hospital also provides comprehensive range of services in the areas of :

• Renal Sciences
  
• General Surgery
  
• Plastic Surgery
  
• Oncology
  
• Gastroenterology
  
• Internal Medicine
  
• Gynaecology and Obstetrics
  
• Orthopaedic & Trauma Care
  
• Dentistry
  
• Psychiatry
  
• Ophthalmology
  
• Dermatology
  
• Neurology
  
• ENT
  
• Neurosurgery
  
• Preventive Health Checkup.
  

Besides, it also has a Diet Clinic, Dialysis Centre, comprehensive Physiotherapy department, 24 hours Emergency Care, 24 hours ambulance service, Diagnostics, Comprehensive Lab medicine, Radiology and a 24 hours pharmacy.

Fortis will leverage its expertise to further strengthen the existing medical programme, upgrade and expand the facility, add new specialties and replicate its operating systems to provide superior medical and patient care.

Speaking at the occasion, Mr. Shivinder Mohan Singh, CEO and Managing Director, Fortis Healthcare Limited said, “We are pleased to announce our entry into the vibrant capital of Karnataka. This is a step forward to realize our vision of becoming a strong national player and brings the FORTIS brand of healthcare to the people of the state. Southern and Western India shall continue to be focus of our network expansion plans.”

Kindly visit http://www.fortishealthcare.com

Fortis Healthcare goes International by foraying into Mauritius

Fortis Healthcare Ltd., one of India’s leading private chains of hospitals announces its first foray into the International healthcare market. Fortis, through one of its wholly owned subsidiary, has joined hands with a diversified Mauritian Industrial Group CIEL, through its subsidiary Novelife Limited, to acquire jointly a controlling stake in Mauritius’s largest private hospital, “Clinique Darné,” now rechristened Fortis Clinique Darné

Fortis Clinique Darné is one of the most modern medical centres in Mauritius, combining the traditions of dedicated personal care with hi-tech facilities and offering wide range of general and specialized medical services in a caring and friendly environment. Fortis plans to use this strategic entry into Mauritius to spread its footprints in developed markets and replicate its successful business model.

Fortis has also taken over the operations and management of the hospital and plans to develop the hospital into a large super specialty hospital in the region. Fortis Clinique Darné has adequate potential for growth keeping in mind its six acre property and the size of the market in Mauritius and neighboring countries.

Fortis Clinique Darné represents a strategic acquisition

Mauritius Healthcare is dominated by public sector hospitals, community and health centres that are under-equipped in terms of infrastructure and medical skills. Many Mauritians have to travel to other countries for high end treatment. This would enable Fortis to leverage Medical Value Travel by creating a gateway to Fortis Network of hospitals within India, as also develop Fortis Clinique Darné as a hub for Medical Tourism in Mauritius. Mauritius, with nine lakhs tourists visiting every year, presents ample opportunity to promote medical tourism for elective procedures and minor surgeries.

Fortis, through this acquisition will get a seamless entry into Mauritius where majority of the population is of Indian origin. Fortis Clinique Darné is evenly poised to leverage Fortis’ expertise and experience of operating super specialty hospitals to upgrade the clinical level of its medical programme to tertiary care and grow significantly in size. Fortis, with its wide network of telemedicine in African countries, would also help evolve Fortis Clinique Darné as a super specialty centre for neighboring countries.

Commenting on the occasion, Mr. Shivinder Mohan Singh, CEO and Managing Director, Fortis Healthcare Ltd. said, “This deal marks Fortis’s first foray internationally. We are very excited about this opportunity to work with our partners to develop tertiary level quality healthcare in the Mascareignes region. This deal is a clear indication of India’s rise in the International healthcare space and we are privileged to be leading that transformation.”

About Fortis Clinique Darné

• Fortis Clinique Darné, with an installed bed capacity of 120 beds , is the Leading private hospital in Mauritius.
  
• Perceived to be the most premium hospital, the hospital caters to the high end populace of the country.
  
• The hospital is located in the populated up-market locality of Floreal, Curepipe and surrounded by residential localities. The location is central and accessible from all parts of Mauritius.
  
• Spread over six acres of land, the hospital offers scope of expanding the bed capacity.
  
• The hospital offers services in various multi specialties including Cardiac, Orthopaedics and Neuro Sciences. It is the only private hospital in Mauritius that undertakes cardiac surgeries.
  
• It is well equipped and has the latest Cath lab and a 64 slice CT scanner
  

For further details contact:

Mr.Sudarshan Mazumdar @ 9810955533

Ms.Pawandeep Kaur @ 9810353439

Fortis Healthcare Ltd.

Also visit website http://www.fortishealthcare.com

Lupin Q3 FY 08-09 – Strong Growth & Consistent Performance with Consolidated Sales up 32% to Rs. 9719 Mn and Net Profit – Rs 1165 Mn

Pharma Major, Lupin Limited, yesterday reported revenues of Rs. 9719 mn for the quarter ended December 2008, a rise of 32 % from revenues of Rs. 7381 mn in the corresponding period last year.

International market revenues at Rs. 6505 mn, recorded a rise of 48%. Of these, Formulation Business in Advanced Markets constituted 77% at Rs. 4990 mn.

Earnings before Interest, Tax, Depreciation and Amortization (EBITDA) were Rs. 1761 mn (Rs. 1477 mn*) a rise of 19%. After Interest and Finance charges of Rs. 146 mn (Rs. 101 mn) and Depreciation of Rs. 219 mn (Rs.175 mn), Profit before Tax grew by 16% to Rs. 1396 mn (Rs. 1202 mn*). Provision for taxation including Fringe Benefit Tax was Rs. 219 mn (Rs. 201 mn*)

Net profit for the quarter was at Rs. 1165 mn. Increase in Net Profit for quarter over the corresponding quarter in the previous year (adjusted for IP income) works out to 16%.

For like representation IP income of Rs 1127 mn for the corresponding quarter of the previous year has been excluded to make the quarters comparable on an operational basis.

Commenting on the Company’s business results, Dr. Kamal Sharma, Managing Director, Lupin, said,”The past ten quarters have been noteworthy. We have continued to outpace and outperform across business segments and markets consistently having steadily consolidated our footprint globally. Recent launches, product approvals and patent settlements, substantial growth in filings, and more importantly – growth in market shares – are an affirmation of the success of our “Strategic Approach” & the effectiveness of our “Go to market” programs. Our strengths in Research & Development and the quality of our Intellectual property is a testimony to Lupin’s vision & commitment to developing and delivering quality & cost-effective drugs for everybody.”

Operational Summary

• Growth in overall Sales in the U.S – Continued Market Leadership in 7 of the 20 products in the market.
  
• Litigation Settlement with Schering-Plough Corporation for Desloratadine®
  
• Hormosan AOK Tender win
  
• Substantial Growth in Filings with two potential First to Files.
  
• Domestic Formulations Business at Rs. 2791 mn – outpaces and outperforms the market with a growth of 27% on net sales basis. (Industry growth as per IMS MAT Nov 08 – 10.3%)
  

Advanced markets

The Company’s Advanced markets formulation business in USA and Europe clocked in sales of Rs 3405 mn during the Q3, 2008-09, ( Q3 2007-08: Rs 2297 mn) reporting a growth of 48%

USA

LPI has garnered a steady growth in prescriptions for generics as well as branded formulations during the quarter. The company achieved market leadership in 7 of the 20 products in the US markets (IMS Sept 08).

Lupin also settled all ongoing Hatch-Waxman litigation relating to Desloratadine tablets, the generic version of Schering-Plough’s “Clarinex”® tablets during the quarter. As per the terms of the settlement, Lupin Ltd. will be licensed under the relevant Desloratadine patents, and free to commercially launch its generic Desloratadine product, on July 1, 2012, or earlier in certain circumstances. Schering-Plough’s Clarinex® tablets had U.S. sales of $329 million for the year 2007-MAT June 2008, according to IMS Health.

Europe

Lupin further consolidated its market position in Europe by completing its acquisition of Hormosan Pharma GmbH (Hormosan), a German generics company specialized in the supply of pharmaceutical products for the Central Nervous System (CNS).

Lupin also reported its first strategic win in the German market through Hormosan in the very first three months post-acquisition – having received information on the results of the Allgemeine Ortskrankenkassen (AOK) Tender, pursuant to § 130a SGB V. Hormosan has been offered 1 products in all 5 regions of Germany covering all AOK-insured persons. The AOK tender process is currently under judicial review.

Hormosan has a strong brand identity in the German generics market through its strong patient compliance message, essential for patients within the CNS sector.

Emerging Markets:

The Formulations revenues from emerging markets including India reported a growth of 24% recording sales of Rs 3236 Mn during Q3, 2008-09 (Rs 2605 Mn, 2007-08)

API revenues from emerging markets (including India) were at Rs 1328 Mn. The Company’s CRAMS business through the new entity Novodigm is progressing well, reporting sales of Rs 125 mn for the third quarter. .

Domestic Market: India:

Company’s domestic formulations business in the third quarter registered gross Sales of Rs. 2791, registering a growth of 27% at the net sales level. For better representation, the sales arising from deemed exports of Rs. 104 mn (Rs.93 mn), and formerly recorded under domestic sales have not been classified along with the domestic formulations business. This growth was driven by the good performance in the CVS, Diabetes, CNS, Asthma and Gastro Segments. The divisions catering to branded segments continued to outpace the industry growing over 29%. Lupin has maintained its leadership in Anti-TB segment and has secured a double digit market share in the anti-asthma market riding high on the strengths of its offerings in this segment.

Other World Markets

The RoW Markets reported sales of Rs 445 Mn for the third quarter recording a growth of 40%.

Japan

Kyowa, the Company’s subsidiary in Japan posted robust sales at Rs 1319 mn registering a growth of 21% over the corresponding period of previous year. The recently launched Amlodipine “Amel” continues to maintain majority market share and Risperidone “Amel”, which was launched last year, continued market leadership in unit terms.

South Africa

Lupin also completed and consolidate its acquisition of a majority stake in Pharma Dynamics (PD) in South Africa. Pharma Dynamics is the fastest growing generic companies in South Africa (over 33% growth for Quarter 3 – 08-09) with a clear leadership in the cardiovascular segment.

PD ranks at number 6 amongst generic companies and is currently growing at 33% per annum as per IMS. The South African Generics Market is currently valued at close to 800 Million USD and growing rapidly.

Research & Development

Progress on Approvals & Filings

Lupin also filed Seven ANDAs filed in the quarter, taking the cumulative ANDA filings total to 76. The company has received 32 approvals to date including Levetiracetam, which has already been launched. Four (4) DMF filings have been made in the quarter, taking the total to 79. The company also filed four (4) MAAs with the European regulatory authorities.

Two (2) Potential first to files were filed in the quarter. Furthermore, litigation was initiated against Lupin on filing the generic versions of Fortamet ER (Metformin extended release tablets) and Antara (Fenofibrate tablets) during the quarter. The company believes that it is the first to file on both. The total tally of first to files stands at eight (8).

About Lupin Limited

Headquartered in Mumbai, India, Lupin Limited is an innovation led transnational pharmaceutical company producing a wide range of quality, affordable generic and branded formulations and APIs for the developed and developing markets of the world.

The Company has secured global leadership position in Anti-TB and Cephalosporins and has a significant presence in the areas of Cardiovasculars (prils and statins), Diabetology, Asthma and NSAIDs. The Company’s R&D endeavors have resulted in significant progress in its NCE program. The Company’s foray into Advanced Drug Delivery Systems has resulted in the development of platform technologies that are being used to develop value-added generic pharmaceuticals.

Currently positioned amongst the top six pharmaceutical companies of India, the Company is committed to achieve sustainable earnings and growth for all its stakeholders.

For the financial year ended March 2008, the Lupin’s Revenues and Profit after Tax were Rs.27,730 million (US$ 694 million) and Rs.4,083 million (US$ 102 million) respectively.

For further information please contact:

Lupin Limited:

Shamsher Gorawara

Head – Corporate Communications

Ph: 9820338555

Email: shamshergorawara@lupinpharma.com

Mr. Ajay Piramal is the India Innovator of the Year

Mr. Ajay Piramal, Chaiman, Piramal Healthcare was adjudged as the India Innovator Of The Year at the CNBC-TV18 India Business Leader Awards presented by Accenture. The award ceremony saw the best in Indian Business come together to salute the finest in Corporate India. Held in Mumbai the awards were graced by the presence of Shri. Kamal Nath, Union Minister of Commerce and Industries, Shri. Ashok Chavan, Chief Minister, Maharashtra, Shri.
Narendra Modi, Chief Minister, Gujarat among others who felicitated the winners.

While accepting the honour, Mr. Piramal said that the task before us is immense. He also hoped that India would be able to invent a drug, a feat that still eludes the country.

The 4^th CNBC-TV18 India Business Leader Awards, India’s most definitive awards in business excellence, felicitated the visionaries who have set shining examples in business leadership over the years. The winners were judged by business leaders
like Mr. Mukesh Ambani, Reliance Industries Ltd. (Chairperson, Jury), Mr. Kumar Mangalam Birla, Chairman, Aditya Birla Group, Mr. Deepak Parekh, Chairman, HDFC, Mr. R. Seshasayee, Managing Director, Ashok Leyland, Mr. Jagdish Khattar, CMD, Carnation Auto India Pvt. Ltd. and Mr.
Raghav Bahl, MD, Network18.

Talking on the parameters on which the winners were selected, Mr. Ambani said, “A leader has to navigate the path and protect the interests of all the stakeholders in a consistent way so that they can deliver performance on an ongoing basis. Also Execution and accomplishments were the main considerations.” According to Mr. Birla, track record is important. Long term viability and sustainability of the business model is also vital. Mr Parekh believes that individual contribution to the company is very important especially in troubled times like these.

Speaking about the awards, Mr. Ajay Chacko, Director, TV18, Business Media said, “India Business Leader Awards are an unparalleled tribute to the excellence in business in India. The awards have become in institution by itself and the winners epitomize strength, ingenuity, knowledge, foresight and who drive the growth of their businesses with vision and inspiration.”

Deccan – India’s First Budget IVF and Keyhole Surgery Centre

India’s first state-of-the-art Budget IVF Clinic and Keyhole Surgery Centre ” Deccan” is an initiative of renowned IVF Specialist Dr Gautam Allahbadia, who has developed the centre in the memory of his late mother in order to offer subsidized IVF services to the poor and the needy. Conveniently located at Shivaji Park, in the heart of Mumbai, the clinic has been developed at par with any other centre with due commitment to technology, techniques and quality and provides all the facilities required to deliver a full range of services to couples requiring assistance conceiving.

The centre offers a comprehensive range of infertility services under one roof, so patients don’t need to shuttle from clinic to lab to the scan center. The practice is restricted to treating infertile patients exclusively, and the clinic offers patients the very best medical care – at affordable prices. Some of the services offered by the clinic are basic work up of the infertile couple, one stop fertility diagnostic services, semen processing, ovulation induction and monitoring, in vitro fertilization, donor egg IVF, embryo freezing, treatment of recurrent pregnancy loss, Diagnostic and operative laparoscopy and hysteroscopy and minimally invasive ultrasound guided procedures.

The Deccan team is led by the Medical Director, Dr Gautam N Allahbadia who coordinates the Infertility & Assisted Conception services along with Dr Prajakta Pawar, the Clinical Associate. The Laboratory Director, Mrs Anjali Awasthi looks after the ART laboratory along with the Biologist, Ms Anuja Tamhane. The Keyhole Surgery Center clinical faculty includes Dr Swati Allahbadia, Dr Pritesh Naik, Dr Rajendra Sankpaland Dr Vivek Salunkhe, who perform Minimally Invasive Fertility Alleviation Surgery for our patients.

Says Dr Gautam Allahbadia,”The opening of Deccan IVF Clinic is special to me. Apart from being India’s first budget IVF Clinic, it is one of our first steps in taking the miracle of life to the masses. We know that facing infertility can be one of the most stressful situations a person can encounter emotionally, physically and financially. We are working towards making the dream of Assisted Reproduction a reality for the common man”.

For further details please visit : http://www.testtubebabyclinic.com/new/default.asp

iSOFT wins US $ 2.78 million deal with Healthscope

iSOFT, an IBA Health Group company, yesterday announced an agreement with leading Australian private hospital provider Healthscope Limited valued at US $ 2.78 million over three years.

The agreement to implement its iSOFT’s software at 38 Healthscope hospitals is in addition to a US $ 9.27 million agreement in December 2007 for software licences and support services over seven years. The initial agreement included pilot implementations of iSOFT’s web-based patient administration solution at two hospitals. Following the success of these pilots, implementation will start shortly at Healthscope’s remaining hospitals, including Knox Private Hospital in Victoria, Allamanda Private Hospital in Queensland and Mount Hospital in Western Australia.

The implementation services covered under the latest agreement include:

• project management
  
• software installation
  
• system configuration
  
• training
  
• migrating medical records and data from a range of legacy systems
  

`Dougall McBurnie, Healthscope’s Group Chief Information Officer said: “Given the marked improvements in feature and function from iSOFT’s web-based patient administration solution experienced at the two pilot installations, we have elected to roll-out the solution to all of our hospitals, thus standardising our data sets, configurations and business processes.” He further added, “The ease of implementation of a common group-wide solution and smooth transition to a modern solution with minimal disruption for staff is a huge bonus.”

Healthscope, one of Australia’s largest private healthcare operators, owns or manages medical/surgical, rehabilitation and psychiatric hospitals. It also operates a leading pathology business with facilities in Australia, New Zealand, Singapore and Malaysia.

iSOFT, an IBA Health Group company, is one of the world’s largest providers of healthcare IT solutions. It designs, builds and delivers industry-leading software systems that serve the entire health sector. iSOFT’s capacity to embrace change and keep abreast of emerging new directions in healthcare allows its customers to explore the exciting potential of new technologies while securing their existing investments. Today, over 13,000 provider organizations in 35 countries across five continents use iSOFT solutions to manage patient information and drive improvements in core processes. Its solutions are a catalyst for change, increasing efficiencies and providing direct benefits to all stakeholders across the whole spectrum of care. iSOFT’s business is driven by the collective talent, experience and commitment of over 4,000 specialists around the globe. iSOFT Global Development Centres of Excellence in Chennai and Bangalore contribute strategically to this international footprint.

For further details, please contact:

Ramesh Karajgikar

iSOFT – An IBA Health Group Company

Mobile: +91 (0) 97910 35005

Email: ramesh.karagikar@isoftplc.com

Cryo-Save India forays into the Western region

Cryo-Save India, the 100% Indian subsidiary of Cryo-Save Group, announced their foray into the western region of the country by launching a full-fledged marketing set-up in Mumbai. The new office is part of their strategic plan for India and is envisioned to further strengthen the company’s position in the Indian market. To cater to parents growing need of providing bio-insurance to their offspring, Cryo-Save India has plans for a phased launch in key centres across the country. In Maharashtra, the city of Mumbai alone has 50,000 births per year and Pune has over 20,000 births every year in the Sec (Socio-Economic classification) A & A+ category. The company’s sales office is head quartered in Mumbai and their Maharashtra plans include representation in cities like Nagpur, Aurangabad, Pune, etc.

Cryo-Save India, with its corporate office in Bangalore, was recently set up with an investment of 1.8 Million Euros. Cryo-Save Group will scale up its investment to 2 million Euros within a year of its operation of the Indian subsidiary. The group company, Europe’s largest adult stem cell storage bank, has its operations in 37 countries across three continents. Cryo-Save India brings to the table a depth of expertise and experience in stem cell banking.

Cryo-Save India will be the only company in India with its unique offering of dual-storage system and this will be available for the first time in the country. They are also the only company that does automatic processing to avoid manual intervention and contamination. The company will be offering the collection and storage of ADULT stem cells derived from cord blood. The services will be available across all metros and other cities.

V.R. Chandramouli, Managing Director, Cryo-Save India, said, “We are very keen to extend our footprint to India specifically in the Western market as we see an immense market potential for adult stem cell banking or family banking in the Maharashtra region. A world-class stem cell banking service was the need of the hour for a huge market like India and Cryo-Save India will be offering this. We believe that the launch of the Indian operations has ushered in a new chapter in the quality of stem cell banking services offered.”

For more details on Cryo-Save India please visit http://www.cryo-save.com/india/index.html

Nobel Biocare imparts knowledge through finest dental programs

When the leaders in consultative solution selling, work in close association with your clinician, the outcome will be the result of deep seeded dental knowledge and an understanding of your smile. No more have the dental clinics in India remained plainly the consumer banks for just tooth caps and bridges. The education of the dental world in the innovative modern methods of restorative dentistry gives you the benefit of aesthetically accurate dental solutions.

In India, Nobel Biocare forged ahead in the area of professional education with over 300 dentists trained through their benchmark NobelFellow program that has seen a successful run spanning three years and over 50 batches. Globally, with 40 years of scientific research experience up their sleeves, Nobel Biocare collaborates its presence with 60 universities and over 600 scientists in 28 countries. They vest their expertise in their own clinical research and development organizations in seven countries – Sweden, Switzerland, Germany, Italy, US, Japan, and China.

While the company does involve itself with formal education programs for graduates and under-graduates at universities across the world, in India it also helps in training modules on implants in dental schools and in-house training of already practicing dentists and super specialists to use refined techniques to practice precise implants. They have a dedicated and trained sales team that offers support and coverage to dental professionals across the length and breadth of our vast nation. Their team of in-house dentists, training coordinators, customer support, marketing and logistics professionals are all trained to provide your trusted dentist with excellent support. Then whether your need is a general one or one that requires specialized attention, NobelFellow trained dental professionals will keep you smiling.

Their efforts at taking professional education and support to the next level is enabled by their offering of WebEx training and support to their mentors, clinicians and laboratory partners wherein they can achieve excellence in the latest happenings in a virtually real environment. With support materials like the demonstration of live surgeries through clinically documented training concepts, hands on exercises and dedicated Mentor direction, their partner clinicians have the added advantage of high end permanent solution even with a routine conventional dental job.

NobelFellow is a 12-day comprehensive interactive course presented over six months in four different modules of three days each. It provides step-by-step coaching for dentists on the application and integration of Nobel Biocare C&B&I (crown, bridge & implants) solutions in a dental practice. Each module contains lectures, hands-on sessions and live surgeries. Their hands-on courses are designed to make their products and procedures easy-to-use and understand. The company also offers on-site training in several languages and online education program to create awareness.

Nobel Biocare has done the maximum and the finest of training and education programs for implant education in India. The newly launched Total Implant Proficiency (TIP) program is designed to meet the dearth of expert implantologists across the country by providing a comprehensive course, conducted by some of the best faculties internationally. The main objective of introducing TIP is to train dental professionals on latest and innovative techniques of implantology like NobelGuide on actual patients and provide certification from ICOI (International Congress of Oral Implantologists).

The enamel of an adult’s permanent teeth once lost is irrecoverable. However if the dentist has the right knowledge of the best dentistry practices, the visible difference will be as though the teeth grew back permanently.

For further details please visit www.nobelbiocare.com

Ozonegroup launches “Ozone Evergreens”, India’s 1st affordable city housing project, in Bengaluru

Ozonegroup, announced the launch of ‘Ozone Evergreens’, India’s first affordable city housing project. The 912 unit development is located within Bangalore (off Sarjapur road) and is being developed on a 10 acre prime property comprising of two-bed and three-bed units. Ozone Evergreens is exclusively marketed by ICICI Property Services, a division of ICICI Home Finance Company Ltd.

‘Ozone Evergreens’ will offer high-quality amenities and facilities for its residents. The project has a uniquely designed large club house with an exclusive swimming pool for women, a state-of-art gymnasium, Jacuzzi, kids play room with crèche, indoor games room – table tennis, pool, carom, chess, multipurpose hall with dry kitchen, meeting rooms with conference and business centre and convenience stores for fresh fruits, daily needs, pharmacy, ATMs and Kiosks.

The development has ample amenities. An ambulance for emergency for exclusive use of its residents, swimming pool for men with Jacuzzi, children’s pool with activity zone, an amphitheatre, visitor’s surface parking area, children’s play area with skating
ring, jogging tracks, are just some of the amenities provided at Ozone Evergreens.

Speaking on the occasion, Vasudevan. S, Managing Director, Ozonegroup, said, “Ozonegroup has been working on lowering the bar for home buyers and will now have the unique distinction of being the first real estate development company to develop and offer a ‘city based affordable housing project’. We are sure ‘Ozone Evergreens’ will set a new benchmark in affordable housing projects.” “Ozonegroup through ‘Ozone Evergreens’ project will be fulfilling the aspiring need for quality, affordable housing for the customer”, he added.

Headquartered in Bangalore with offices in Chennai and Goa, the group currently has projects in Bangalore, Chennai and Goa. All projects of Ozonegroup are aesthetically designed with world class architectural capabilities. The projects offer a variety of amenities for customers which enable them to lead a better quality of life. In addition, the projects are designed with an emphasis on being very environmentally responsible. The development will have unique water management and conservation systems. Rainwater Harvesting systems and primary and tertiary water treatment will recycle and reuse black as well as grey water, thus conserving both ground water sources as well as municipal water.

Added Sudarshan K.S, Chief Operating Officer, Ozonegroup, “We have been working on making homes affordable to a larger segment of the population and Ozone Evergreens is the first small step to make homes affordable for a large section of the city’s population. We have worked diligently in optimizing the designs resulting in Ozone Evergreens having high quality, safety and finish. Ozone Evergreens has fully loaded amenities that would re-define the meaning of affordable housing in India. This project will set the benchmark for value-for-money real estate products.” Adding further, he said, “The units are uniquely designed so that units do not face each other, utilize natural lighting in the best possible way, face either the background greenery or the landscape and the structures are Seismic Zone II compliant.”

Evergreens will be ready for occupation by February 2011.

You can visit www.ozonegroup.com for further information.